Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Freudenreich, Oliver
2020.
Psychotic Disorders.
p.
171.
Torrisi, Sebastiano Alfio
Laudani, Samuele
Contarini, Gabriella
De Luca, Angelina
Geraci, Federica
Managò, Francesca
Papaleo, Francesco
Salomone, Salvatore
Drago, Filippo
and
Leggio, Gian Marco
2020.
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments.
Pharmaceuticals,
Vol. 13,
Issue. 11,
p.
365.
Hernández-Huerta, Daniel
and
Morillo-González, Jessenia
2021.
Dopamine D3 partial agonists in the treatment of psychosis and substance use disorder comorbidity: a pharmacological alternative to consider?.
CNS Spectrums,
Vol. 26,
Issue. 5,
p.
444.
Laszlovszky, István
Barabássy, Ágota
and
Németh, György
2021.
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
Advances in Therapy,
Vol. 38,
Issue. 7,
p.
3652.
Dodić, Sara
Dunjić-Kostić, Bojana
Jerotić, Stefan
Lalović, Nikola
Ivković, Maja
and
Pantović-Stefanović, Maja
2021.
Cariprazine in the treatment of unipolar depression: Case report.
Engrami,
Vol. 43,
Issue. 1,
p.
82.
Dubatova, Irina Vladimirovna
Antsyborov, Lema Andreevich
Kheigetian, Artur Fedorovich
and
Antsyborov, Andrey Viktorovich
2021.
“Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?.
Interactive science,
p.
9.
Yan, Wenzhong
Fan, Luyu
Yu, Jing
Liu, Ruiquan
Wang, Huan
Tan, Liang
Wang, Sheng
and
Cheng, Jianjun
2021.
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D2 Receptor Partial Agonists: Design, Synthesis, and Biological Evaluation.
Journal of Medicinal Chemistry,
Vol. 64,
Issue. 23,
p.
17239.
Berardis, Domenico De
Rapini, Gabriella
Olivieri, Luigi
Giardini, Agostina
Lauretis, Ida De
Serroni, Nicola
Orsolini, Laura
Fornaro, Michele
Iasevoli, Felice
Trotta, Sabatino
Cottura, Paolo
Vellante, Federica
Alessandrini, Marco
and
Giannantonio, Massimo Di
2021.
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.
Clinical Psychopharmacology and Neuroscience,
Vol. 19,
Issue. 1,
p.
174.
Cosi, Cristina
Martel, Jean-Claude
Auclair, Agnès L.
Collo, Ginetta
Cavalleri, Laura
Heusler, Peter
Leriche, Ludovic
Gaudoux, Florence
Sokoloff, Pierre
Moser, Paul C.
and
Gatti-McArthur, Silvia
2021.
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist.
European Journal of Pharmacology,
Vol. 890,
Issue. ,
p.
173635.
Thomson, David M.
Openshaw, Rebecca L.
Mitchell, Emma J.
Kouskou, Marianna
Millan, Mark J.
Mannoury la Cour, Clotilde
Morris, Brian J.
and
Pratt, Judith A.
2021.
Impaired working memory, cognitive flexibility and reward processing in mice genetically lacking Gpr88: Evidence for a key role for Gpr88 in multiple cortico‐striatal‐thalamic circuits.
Genes, Brain and Behavior,
Vol. 20,
Issue. 2,
Batinic, Borjanka
Ristic, Ivan
Zugic, Milica
and
Baldwin, David S.
2021.
Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine.
Frontiers in Psychiatry,
Vol. 12,
Issue. ,
Müller, Helge HO
and
Moeller, Sebastian
2021.
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases.
Neuropsychiatric Disease and Treatment,
Vol. Volume 17,
Issue. ,
p.
1089.
Dallérac, Glenn
Li, Xia
Lecouflet, Pierre
Morisot, Nadège
Sacchi, Silvia
Asselot, Rachel
Pham, Thu Ha
Potier, Brigitte
Watson, David J. G.
Schmidt, Staffan
Levasseur, Grégoire
Fossat, Pascal
Besedin, Andrey
Rivet, Jean-Michel
Coyle, Joseph T.
Collo, Ginetta
Pollegioni, Loredano
Kehr, Jan
Galante, Micaela
Fone, Kevin C.
Gardier, Alain M.
Freret, Thomas
Contarino, Angelo
Millan, Mark J.
and
Mothet, Jean-Pierre
2021.
Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist
d
-serine
.
Proceedings of the National Academy of Sciences,
Vol. 118,
Issue. 23,
Torrisi, Sebastiano Alfio
Geraci, Federica
Contarini, Gabriella
Salomone, Salomone
Drago, Filippo
and
Leggio, Gian Marco
2022.
Therapeutic Applications of Dopamine D3 Receptor Function.
Vol. 60,
Issue. ,
p.
133.
Németh, György
Dombi, Zsófia B.
Laszlovszky, István
and
Barabássy, Ágota
2022.
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases.
Expert Opinion on Pharmacotherapy,
Vol. 23,
Issue. 12,
p.
1467.
Sachs, Gabriele
and
Erfurth, Andreas
2022.
Wirkungen von Cariprazin auf Negativsymptome und kognitive Störungen bei Schizophrenie.
psychopraxis. neuropraxis,
Vol. 25,
Issue. 3,
p.
166.
Bajouco, Miguel
and
Mota, David
2022.
Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series.
Neuropsychiatric Disease and Treatment,
Vol. Volume 18,
Issue. ,
p.
1351.
Nasyrova, R. F.
2022.
Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia.
V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY,
Vol. 56,
Issue. 4,
p.
101.
Rancans, Elmars
Dombi, Zsófia Borbála
and
Barabássy, Ágota
2022.
Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia.
Frontiers in Psychiatry,
Vol. 12,
Issue. ,
Molnar, Maria Judit
Molnar, Viktor
Fedor, Mariann
Csehi, Reka
Acsai, Karoly
Borsos, Beata
and
Grosz, Zoltan
2022.
Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.
Frontiers in Psychiatry,
Vol. 12,
Issue. ,